Stock data
Atossa Therapeutics, Inc. (ATOS)
Atossa Therapeutics, Inc. (ATOS) reported net income of -US$34.77M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$37.14M | -US$34.77M | — |
| 2024 | — | — | -US$27.62M | -US$25.50M | — |
| 2023 | — | — | -US$31.38M | -US$30.09M | — |
| 2022 | — | — | -US$27.69M | -US$26.96M | — |
| 2021 | — | — | -US$20.52M | -US$20.61M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$8.49M | — |
| 2026-03-31 | — | -US$9.59M | — |
| 2025-12-31 | — | -US$10.94M | — |
| 2025-09-30 | — | -US$8.69M | — |
| 2025-06-30 | — | -US$8.42M | — |
| 2025-03-31 | — | -US$6.72M | — |
| 2024-12-31 | — | -US$6.35M | — |
| 2024-09-30 | — | -US$7.23M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.